Vemurafenib: the first drug approved for BRAF-mutant cancer.

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 2.54

Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study. JAMA Intern Med (2014) 2.50

Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Mol Cell (2015) 2.13

Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol (2013) 1.59

MelanomaDB: A Web Tool for Integrative Analysis of Melanoma Genomic Information to Identify Disease-Associated Molecular Pathways. Front Oncol (2013) 1.53

Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell (2014) 1.43

Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research. Ann Transl Med (2015) 1.42

Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery (2015) 1.41

Anthrax lethal and edema toxins in anthrax pathogenesis. Trends Microbiol (2014) 1.33

MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer (2015) 1.27

Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. Cancer Immunol Res (2014) 1.17

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med (2015) 1.15

Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ. Cancer Res (2014) 1.10

Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. J Med Chem (2013) 0.99

MEK targeting in N-RAS mutated metastatic melanoma. Mol Cancer (2014) 0.98

A Quantitative System for Studying Metastasis Using Transparent Zebrafish. Cancer Res (2015) 0.97

Chloroquine promotes apoptosis in melanoma cells by inhibiting BH3 domain-mediated PUMA degradation. J Invest Dermatol (2013) 0.97

Targeting allosteric disulphide bonds in cancer. Nat Rev Cancer (2013) 0.96

Phospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancer. Pharmacol Rev (2014) 0.96

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer (2014) 0.95

The discovery of medicines for rare diseases. Future Med Chem (2014) 0.94

Cancer3D: understanding cancer mutations through protein structures. Nucleic Acids Res (2014) 0.93

Evolutions in fragment-based drug design: the deconstruction-reconstruction approach. Drug Discov Today (2014) 0.93

BRAF inhibition alleviates immune suppression in murine autochthonous melanoma. Cancer Immunol Res (2014) 0.93

Twenty years on: the impact of fragments on drug discovery. Nat Rev Drug Discov (2016) 0.92

Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. Mol Cancer Ther (2014) 0.92

Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain. Pigment Cell Melanoma Res (2013) 0.92

Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor. Proc Natl Acad Sci U S A (2013) 0.91

Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics. Int J Nanomedicine (2013) 0.90

Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. Oncogene (2015) 0.90

Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment. J Natl Cancer Inst (2014) 0.90

Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3. Cell Death Dis (2013) 0.90

Personalizing therapy in advanced non-small cell lung cancer. Semin Respir Crit Care Med (2013) 0.89

Betabox: a beta particle imaging system based on a position sensitive avalanche photodiode. Phys Med Biol (2013) 0.88

Fragment-based discovery of type I inhibitors of maternal embryonic leucine zipper kinase. ACS Med Chem Lett (2014) 0.88

Chemical dissection of the cell cycle: probes for cell biology and anti-cancer drug development. Cell Death Dis (2014) 0.88

Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma. Int J Nanomedicine (2015) 0.87

Remaining challenges in childhood cancer and newer targeted therapeutics. Pediatr Clin North Am (2014) 0.87

Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells. Cell Cycle (2013) 0.86

Omics Profiling in Precision Oncology. Mol Cell Proteomics (2016) 0.85

The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma. Oncotarget (2017) 0.85

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma. Oncol Lett (2013) 0.84

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. PLoS One (2015) 0.84

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model. Oncotarget (2015) 0.84

Opportunities and challenges provided by crosstalk between signalling pathways in cancer. Oncogene (2015) 0.84

Loss of PI(4,5)P2 5-Phosphatase A Contributes to Resistance of Human Melanoma Cells to RAF/MEK Inhibitors. Transl Oncol (2013) 0.83

That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance. Br J Pharmacol (2013) 0.83

Stage-specific prognostic biomarkers in melanoma. Oncotarget (2015) 0.83

An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation. Immunol Res (2014) 0.83

Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review). Oncol Rep (2014) 0.82

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib. Case Rep Oncol (2014) 0.81

BRAF gene: From human cancers to developmental syndromes. Saudi J Biol Sci (2014) 0.81

Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint Approach. J Med Chem (2016) 0.81

Glucose-independent Acetate Metabolism Promotes Melanoma Cell Survival and Tumor Growth. J Biol Chem (2016) 0.80

BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress. Mol Ther (2015) 0.80

Oncogene withdrawal engages the immune system to induce sustained cancer regression. J Immunother Cancer (2014) 0.80

Noncanonical roles of the immune system in eliciting oncogene addiction. Curr Opin Immunol (2013) 0.80

EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile. Cancer Biol Ther (2016) 0.79

Cancer stem cells: a systems biology view of their role in prognosis and therapy. Anticancer Drugs (2014) 0.79

Aberrant expression of COT is related to recurrence of papillary thyroid cancer. Medicine (Baltimore) (2015) 0.79

Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma. Br J Cancer (2016) 0.79

Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models. Genome Biol (2016) 0.79

Lessons from Hot Spot Analysis for Fragment-Based Drug Discovery. Trends Pharmacol Sci (2015) 0.79

Disruption of mutated BRAF signaling modulates thyroid cancer phenotype. BMC Res Notes (2014) 0.78

Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase. Nat Commun (2015) 0.78

Fragment-Based Approaches to the Development of Mycobacterium tuberculosis CYP121 Inhibitors. J Med Chem (2016) 0.78

Covalent targeting of acquired cysteines in cancer. Curr Opin Chem Biol (2015) 0.78

mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib. Oncotarget (2015) 0.78

Partially Saturated Bicyclic Heteroaromatics as an sp(3) -Enriched Fragment Collection. Angew Chem Int Ed Engl (2016) 0.78

Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas. BMC Cancer (2015) 0.78

Activation Status of the Pregnane X Receptor Influences Vemurafenib Availability in Humanized Mouse Models. Cancer Res (2015) 0.77

Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma. ACS Med Chem Lett (2015) 0.77

Growth inhibitory effects of large subunit ribosomal proteins in melanoma. Pigment Cell Melanoma Res (2014) 0.77

Phosphorylation of RAF Kinase Dimers Drives Conformational Changes that Facilitate Transactivation. Angew Chem Int Ed Engl (2015) 0.77

Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway. Drug Des Devel Ther (2014) 0.77

Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma. Mol Cancer Ther (2013) 0.77

DICE: A novel tumor surveillance mechanism-a new therapy for cancer? Cell Cycle (2014) 0.77

A case report and genetic characterization of a massive acinic cell carcinoma of the parotid with delayed distant metastases. Case Rep Oncol Med (2013) 0.77

Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine. ACS Med Chem Lett (2014) 0.76

Using Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer Therapy. Front Pharmacol (2016) 0.76

Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. Oncotarget (2016) 0.76

BRAF-targeted therapy alters the functions of intratumoral CD4(+) T cells to inhibit melanoma progression. Oncoimmunology (2014) 0.76

RASopathy Gene Mutations in Melanoma. J Invest Dermatol (2016) 0.76

Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation. PLoS One (2015) 0.76

Feasibility of ultra-high-throughput functional screening of melanoma biopsies for discovery of novel cancer drug combinations. Clin Cancer Res (2017) 0.76

Tailoring the Treatment of Melanoma: Implications for Personalized Medicine. Yale J Biol Med (2015) 0.75

Key drivers of biomedical innovation in cancer drug discovery. EMBO Mol Med (2014) 0.75

Shifting ecologies of malignant and nonmalignant cells following BRAF inhibition. J Clin Invest (2014) 0.75

Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. J Pharmacol Exp Ther (2015) 0.75

Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAF(V600E) Conformation. ACS Chem Biol (2016) 0.75

BRAF Mutations Open Doors for N-Ethyl-N-Nitrosourea-Induced Gliomagenesis. Am J Pathol (2016) 0.75

Discretization of Gene Expression Data Unmasks Molecular Subgroups Recurring in Different Human Cancer Types. PLoS One (2016) 0.75

An overview of recommendations and translational milestones for genomic tests in cancer. Genet Med (2014) 0.75

Multifocal BRAF(V600E)-Mutated Melanoma in situ on the Foot. Case Rep Dermatol (2015) 0.75

Pragmatic medicine in solid cancer: a translational alternative to precision medicine. Onco Targets Ther (2016) 0.75

Rhomboids, signalling and cell biology. Biochem Soc Trans (2016) 0.75

Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs. Cancer Sci (2016) 0.75

Substrate Fragmentation for the Design of M. tuberculosis CYP121 Inhibitors. ChemMedChem (2016) 0.75

Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression. BMC Res Notes (2014) 0.75

IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis. BMC Cancer (2016) 0.75

Mutations of the BRAF gene in human cancer. Nature (2002) 65.42

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31

Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28

BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14

BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature (2005) 16.87

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39

Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer (2007) 10.27

High frequency of BRAF mutations in nevi. Nat Genet (2002) 9.95

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39

Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer (2009) 9.26

High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res (2003) 8.67

BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature (2012) 8.13

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81

Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46

BRAF mutations in hairy-cell leukemia. N Engl J Med (2011) 7.05

A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell (2006) 6.96

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov (2006) 6.88

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A (2010) 6.54

Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res (2008) 6.44

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21

BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst (2003) 6.20

Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature (1994) 6.16

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05

Activation of the MAP kinase pathway by the protein kinase raf. Cell (1992) 5.95

Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell (2005) 5.88

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med (2010) 5.57

A dimerization-dependent mechanism drives RAF catalytic activation. Nature (2009) 5.39

A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev (2007) 5.07

Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol (1999) 4.98

Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood (2010) 4.96

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun (2012) 4.94

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab (2003) 4.93

Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc Natl Acad Sci U S A (1983) 4.82

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 4.80

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov (2012) 4.72

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res (2010) 4.70

Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature (1993) 4.61

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res (2010) 4.50

V599EB-RAF is an oncogene in melanocytes. Cancer Res (2004) 4.49

Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res (2003) 4.28

Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell (2005) 4.24

Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res (2001) 4.20

Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res (2003) 4.03

BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest (2008) 3.98

Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut (2003) 3.91

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol (2011) 3.66

B-RAF is a therapeutic target in melanoma. Oncogene (2004) 3.61

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol (2011) 3.43

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal (2010) 3.25

BRAF mutations in papillary carcinomas of the thyroid. Oncogene (2003) 2.94

Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res (2006) 2.84

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer (2010) 2.83

Serine- and threonine-specific protein kinase activities of purified gag-mil and gag-raf proteins. Nature (1985) 2.82

Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res (2006) 2.65

Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol (2008) 2.61

Resistance to BRAF inhibition in melanomas. N Engl J Med (2011) 2.58

BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res (2008) 2.57

A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol (2005) 2.51

Technology platforms for pharmacogenomic diagnostic assays. Nat Rev Drug Discov (2004) 2.50

High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res (2003) 2.49

The rise of fragment-based drug discovery. Nat Chem (2009) 2.46

Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res (2010) 2.42

Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist (2009) 2.37

Oligomerization activates c-Raf-1 through a Ras-dependent mechanism. Nature (1996) 2.29

BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med (2012) 2.25

DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature (2011) 2.23

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res (2011) 2.22

Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol (2012) 2.21

Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene (2011) 2.10

A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature (2011) 2.07

BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One (2011) 2.04

Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF. PLoS One (2009) 2.03

PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res (2010) 2.02

The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res (2010) 2.02

A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res (2008) 1.99

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer (2008) 1.99

The complete coding sequence of the human A-raf-1 oncogene and transforming activity of a human A-raf carrying retrovirus. Nucleic Acids Res (1987) 1.98

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest (2011) 1.97

Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol Cell Biol (2009) 1.81

Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. J Mol Biol (2005) 1.79

Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res (2011) 1.79

B-raf, a new member of the raf family, is activated by DNA rearrangement. Mol Cell Biol (1988) 1.78

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12

IRE1 signaling affects cell fate during the unfolded protein response. Science (2007) 9.01

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A (2010) 6.54

Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science (2005) 5.53

Inhibitor hijacking of Akt activation. Nat Chem Biol (2009) 4.91

A critical assessment of Mus musculus gene function prediction using integrated genomic evidence. Genome Biol (2008) 4.78

Genome-wide analysis of PTB-RNA interactions reveals a strategy used by the general splicing repressor to modulate exon inclusion or skipping. Mol Cell (2009) 4.71

The unfolded protein response signals through high-order assembly of Ire1. Nature (2008) 3.87

Bypassing a kinase activity with an ATP-competitive drug. Science (2003) 3.71

Chemical genetic analysis of the time course of signal transduction by JNK. Mol Cell (2006) 3.32

A chemical-genetic approach to studying neurotrophin signaling. Neuron (2005) 2.93

Control of landmark events in meiosis by the CDK Cdc28 and the meiosis-specific kinase Ime2. Genes Dev (2003) 2.79

Chemical genetic analysis of Apg1 reveals a non-kinase role in the induction of autophagy. Mol Biol Cell (2003) 2.72

Selective amygdalohippocampectomy versus anterior temporal lobectomy in the management of mesial temporal lobe epilepsy: a meta-analysis of comparative studies. J Neurosurg (2013) 2.71

A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol (2005) 2.51

Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol (2007) 2.43

Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells. Proc Natl Acad Sci U S A (2007) 2.37

Phosphoproteomic analysis reveals interconnected system-wide responses to perturbations of kinases and phosphatases in yeast. Sci Signal (2010) 2.36

JNK2 is a positive regulator of the cJun transcription factor. Mol Cell (2006) 2.32

Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in Toxoplasma. Nature (2010) 2.25

Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol Cell (2007) 2.22

An integrated platform of genomic assays reveals small-molecule bioactivities. Nat Chem Biol (2008) 2.21

Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol (2012) 2.21

TFIIH-associated Cdk7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II. Mol Cell Biol (2009) 2.20

Re-emerging superconductivity at 48 kelvin in iron chalcogenides. Nature (2012) 2.13

An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol (2005) 2.11

The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med (2015) 2.07

Mps1 directs the assembly of Cdc20 inhibitory complexes during interphase and mitosis to control M phase timing and spindle checkpoint signaling. J Cell Biol (2010) 2.07

The Saccharomyces cerevisiae Mob2p-Cbk1p kinase complex promotes polarized growth and acts with the mitotic exit network to facilitate daughter cell-specific localization of Ace2p transcription factor. J Cell Biol (2002) 2.04

PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res (2010) 2.02

Inducible protein knockout reveals temporal requirement of CaMKII reactivation for memory consolidation in the brain. Proc Natl Acad Sci U S A (2003) 1.93

A global representation of the protein fold space. Proc Natl Acad Sci U S A (2003) 1.88

Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer (2011) 1.84

Phosphorylation of the transcription elongation factor Spt5 by yeast Bur1 kinase stimulates recruitment of the PAF complex. Mol Cell Biol (2009) 1.82

Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. J Mol Biol (2005) 1.79

Plk1 self-organization and priming phosphorylation of HsCYK-4 at the spindle midzone regulate the onset of division in human cells. PLoS Biol (2009) 1.78

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med (2015) 1.75

Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Nat Struct Mol Biol (2012) 1.74

Chemical genetics reveals a role for Mps1 kinase in kinetochore attachment during mitosis. Curr Biol (2005) 1.70

Cdc28-Clb5 (CDK-S) and Cdc7-Dbf4 (DDK) collaborate to initiate meiotic recombination in yeast. Genes Dev (2008) 1.68

Low-risk lifestyle behaviors and all-cause mortality: findings from the National Health and Nutrition Examination Survey III Mortality Study. Am J Public Health (2011) 1.68

Suppression of p53-dependent senescence by the JNK signal transduction pathway. Proc Natl Acad Sci U S A (2007) 1.67

The crystal structures of human steroidogenic factor-1 and liver receptor homologue-1. Proc Natl Acad Sci U S A (2005) 1.67

TFIIH and P-TEFb coordinate transcription with capping enzyme recruitment at specific genes in fission yeast. Mol Cell (2009) 1.66

Mek1 kinase activity functions downstream of RED1 in the regulation of meiotic double strand break repair in budding yeast. Mol Biol Cell (2003) 1.66

A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol Cell (2004) 1.64

Global mapping of the protein structure space and application in structure-based inference of protein function. Proc Natl Acad Sci U S A (2005) 1.59

Vitamin D and all-cause mortality among adults in USA: findings from the National Health and Nutrition Examination Survey Linked Mortality Study. Int J Epidemiol (2011) 1.58

Trends in in-hospital deaths among hospitalizations with pulmonary embolism. Arch Intern Med (2012) 1.53

Chemical genetic inhibition of Mps1 in stable human cell lines reveals novel aspects of Mps1 function in mitosis. PLoS One (2010) 1.50

11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol Imaging (2003) 1.49

Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia (2010) 1.48

Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid (2013) 1.45

[Responses of spatial distribution pattern of Artemisia ordosica population to the precipitation gradient on Ordos Plateau]. Ying Yong Sheng Tai Xue Bao (2009) 1.44

Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2 subunits. J Biol Chem (2007) 1.43

A genetically selective inhibitor demonstrates a function for the kinase Zap70 in regulatory T cells independent of its catalytic activity. Nat Immunol (2010) 1.42

A coupled chemical-genetic and bioinformatic approach to Polo-like kinase pathway exploration. Chem Biol (2007) 1.42

Access denied: Snf1 activation loop phosphorylation is controlled by availability of the phosphorylated threonine 210 to the PP1 phosphatase. J Biol Chem (2007) 1.42

Human Ago2 is required for efficient microRNA 122 regulation of hepatitis C virus RNA accumulation and translation. J Virol (2010) 1.42

Engineering the cell-material interface for controlling stem cell adhesion, migration, and differentiation. Biomaterials (2011) 1.41

Waist circumference, abdominal obesity, and depression among overweight and obese U.S. adults: National Health and Nutrition Examination Survey 2005-2006. BMC Psychiatry (2011) 1.38

Design and use of analog-sensitive protein kinases. Curr Protoc Mol Biol (2004) 1.37

Room temperature giant and linear magnetoresistance in topological insulator Bi2Te3 nanosheets. Phys Rev Lett (2012) 1.34

Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther (2007) 1.33

Protein kinase Cdelta regulates ethanol intoxication and enhancement of GABA-stimulated tonic current. J Neurosci (2008) 1.32

Structure and substrate recruitment of the human spindle checkpoint kinase Bub1. Mol Cell (2008) 1.32

Distinct activation pathways confer cyclin-binding specificity on Cdk1 and Cdk2 in human cells. Mol Cell (2008) 1.32

Construction of conditional analog-sensitive kinase alleles in the fission yeast Schizosaccharomyces pombe. Nat Protoc (2007) 1.32

The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. Nanomedicine (2009) 1.32

Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach. Cancer Res (2003) 1.32

Intraglottal pressure distributions for a symmetric and oblique glottis with a uniform duct. J Acoust Soc Am (2002) 1.31

Rapid self-healing hydrogels. Proc Natl Acad Sci U S A (2012) 1.29

Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J Med Chem (2004) 1.29

Orm protein phosphoregulation mediates transient sphingolipid biosynthesis response to heat stress via the Pkh-Ypk and Cdc55-PP2A pathways. Mol Biol Cell (2012) 1.28

Dynamic phosphoregulation of the cortical actin cytoskeleton and endocytic machinery revealed by real-time chemical genetic analysis. J Cell Biol (2003) 1.27

Internal fixation of distal tibiofibular syndesmotic injuries: a systematic review with meta-analysis. Int Orthop (2013) 1.23

FastContact: rapid estimate of contact and binding free energies. Bioinformatics (2005) 1.22

Switching Cdk2 on or off with small molecules to reveal requirements in human cell proliferation. Mol Cell (2011) 1.21

Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by Toxoplasma gondii. J Med Chem (2013) 1.19

Tissue-specific PKA inhibition using a chemical genetic approach and its application to studies on sperm capacitation. Proc Natl Acad Sci U S A (2008) 1.18

Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase. Proc Natl Acad Sci U S A (2006) 1.18

Inhibition of ZAP-70 kinase activity via an analog-sensitive allele blocks T cell receptor and CD28 superagonist signaling. J Biol Chem (2008) 1.15